CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment
暂无分享,去创建一个
K. Blennow | H. Zetterberg | M. Bjerke | S. Rolstad | C. Ekman | M. Landén | C. Sellgren | E. Pålsson | A. Isgren | J. Jakobsson
[1] À. Rovira,et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. , 2015, Brain : a journal of neurology.
[2] J. Frederiksen,et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis , 2015, Multiple sclerosis.
[3] K. Blennow,et al. CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment , 2014, Journal of Neuroimmunology.
[4] I. Melle,et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta‐analysis , 2013, Acta psychiatrica Scandinavica.
[5] L. Schlichter,et al. The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion , 2013, Journal of Neuroinflammation.
[6] M. Landén,et al. The societal cost of bipolar disorder in Sweden , 2013, Social Psychiatry and Psychiatric Epidemiology.
[7] Janet B W Williams,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[8] D. Kupfer,et al. Bipolar disorder diagnosis: challenges and future directions , 2013, The Lancet.
[9] K. Blennow,et al. Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder , 2013, Neuropsychopharmacology.
[10] C. Ekman,et al. Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls , 2012, BMC Psychiatry.
[11] M. Portella,et al. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study , 2012, Psychological Medicine.
[12] K. Blennow,et al. Biomarkers for Microglial Activation in Alzheimer's Disease , 2011, International journal of Alzheimer's disease.
[13] Michael F. Green,et al. The impact of neurocognitive impairment on occupational recovery of clinically stable patients with bipolar disorder: a prospective study , 2011, Bipolar disorders.
[14] R. Kessler,et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. , 2011, Archives of general psychiatry.
[15] M. Berk,et al. eview athways underlying neuroprogression in bipolar disorder : Focus on nflammation , oxidative stress and neurotrophic factors , 2010 .
[16] Chengjie Xiong,et al. YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.
[17] S. Sakoda,et al. Serum inflammatory proteins and frontal lobe dysfunction in patients with cardiovascular risk factors , 2010, European journal of neurology.
[18] S. Rapoport,et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients , 2010, Molecular Psychiatry.
[19] À. Rovira,et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. , 2010, Brain : a journal of neurology.
[20] Klaus P. Ebmeier,et al. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. , 2009, The British journal of psychiatry : the journal of mental science.
[21] M. Thase,et al. A history of childhood attention‐deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD , 2009, Acta psychiatrica Scandinavica.
[22] R. McIntyre,et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. , 2009, The Journal of clinical psychiatry.
[23] E. Bora,et al. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. , 2009, Journal of affective disorders.
[24] M. Portella,et al. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. , 2008, The Journal of clinical psychiatry.
[25] Tiao-Lai Huang,et al. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[26] W. Scheper,et al. The significance of neuroinflammation in understanding Alzheimer’s disease , 2006, Journal of Neural Transmission.
[27] Peter Gallagher,et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. , 2006, Journal of affective disorders.
[28] I. Ferrier,et al. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. , 2006, Bipolar disorders.
[29] H. Ling,et al. Inflammatory Cytokines Induce Production of CHI3L1 by Articular Chondrocytes* , 2005, Journal of Biological Chemistry.
[30] B. Maier,et al. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. , 2005, Journal of neurotrauma.
[31] J. Savitz,et al. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. , 2005, Bipolar disorders.
[32] A. H. Berman,et al. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in Criminal Justice and Detoxification Settings and in a Swedish Population Sample , 2004, European Addiction Research.
[33] D. Kupfer,et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) , 2003, Biological Psychiatry.
[34] S. Lorenzl,et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases , 2003, Journal of the Neurological Sciences.
[35] G. Devercelli,et al. Health care utilization and costs among privately insured patients with bipolar I disorder. , 2002, Bipolar disorders.
[36] J. Lundgren,et al. YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis , 2002, Clinical and Vaccine Immunology.
[37] J. Johansen,et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. , 1999, Rheumatology.
[38] O. Aasland,et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. , 1993, Addiction.
[39] D. Mackinnon,et al. Estimating Mediated Effects in Prevention Studies , 1993 .
[40] Henrik Zetterberg,et al. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. , 2013, Journal of Alzheimer's disease : JAD.
[41] K. Blennow,et al. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. , 2011, Journal of Alzheimer's disease : JAD.
[42] K. Blennow,et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[43] K. Brew,et al. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.
[44] Kenneth J Sher,et al. The development of alcohol use disorders. , 2005, Annual review of clinical psychology.
[45] A. Muijsers,et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. , 1998, European journal of biochemistry.
[46] D. Sheehan,et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.
[47] T. Hergueta,et al. The mini international neuropsychiatric interview , 1998, European Psychiatry.
[48] K. Blennow,et al. Journal of Central Nervous System Disease , 2022 .